OPKO Health Inc. [NASDAQ: OPK] stock went on an upward path that rose over 3.40% on Wednesday, amounting to a one-week price increase of more than 6.61%. The company report on June 2, 2022 that OPKO Health to Present at the 2022 Jefferies Healthcare Conference.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the 2022 Jefferies Healthcare Conference taking place June 8-10, 2022 in New York City. Management will be participating in a fireside chat on Thursday, June 9th at 8:00 a.m. Eastern time and will be hosting one-on-one meetings with investors.
The fireside chat will be webcast live and available for replay in the Investors section of OPKO Health’s website by clicking here.
Over the last 12 months, OPK stock dropped by -30.28%. The one-year OPKO Health Inc. stock forecast points to a potential upside of 57.85. The average equity rating for OPK stock is currently 1.80, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.80 billion, with 660.30 million shares outstanding and 410.92 million shares in the current float. Compared to the average trading volume of 4.86M shares, OPK stock reached a trading volume of 3162559 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on OPKO Health Inc. [OPK]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for OPK shares is $6.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on OPK stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barrington Research have made an estimate for OPKO Health Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on January 24, 2022. While these analysts kept the previous recommendation, Ladenburg Thalmann raised their target price to Buy. The new note on the price target was released on June 21, 2021, representing the official price target for OPKO Health Inc. stock. Previously, the target price had yet another raise to $2.50, while Piper Jaffray analysts kept a Overweight rating on OPK stock.
The Average True Range (ATR) for OPKO Health Inc. is set at 0.17, with the Price to Sales ratio for OPK stock in the period of the last 12 months amounting to 1.15. The Price to Book ratio for the last quarter was 1.12, with the Price to Cash per share for the same quarter was set at 0.16.
OPK Stock Performance Analysis:
OPKO Health Inc. [OPK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.61. With this latest performance, OPK shares dropped by -7.12% in over the last four-week period, additionally sinking by -44.42% over the last 6 months – not to mention a drop of -30.28% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OPK stock in for the last two-week period is set at 52.56, with the RSI for the last a single of trading hit 58.15, and the three-weeks RSI is set at 49.90 for OPKO Health Inc. [OPK]. The present Moving Average for the last 50 days of trading for this stock 2.78, while it was recorded at 2.63 for the last single week of trading, and 3.50 for the last 200 days.
Insight into OPKO Health Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and OPKO Health Inc. [OPK] shares currently have an operating margin of -0.81 and a Gross Margin at +30.30. OPKO Health Inc.’s Net Margin is presently recorded at -1.70.
Return on Equity for this stock declined to -1.80, with Return on Assets sitting at -1.24.
OPKO Health Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 2.40.
OPK Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OPK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for OPKO Health Inc. go to 12.00%.
OPKO Health Inc. [OPK] Insider Position Details
There are presently around $518 million, or 29.60% of OPK stock, in the hands of institutional investors. The top three institutional holders of OPK stocks are: VANGUARD GROUP INC with ownership of 36,072,131, which is approximately 0.97% of the company’s market cap and around 0.50% of the total institutional ownership; BLACKROCK INC., holding 33,870,368 shares of the stock with an approximate value of $89.76 million in OPK stocks shares; and STATE STREET CORP, currently with $73.38 million in OPK stock with ownership of nearly 56.658% of the company’s market capitalization.
Positions in OPKO Health Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 90 institutional holders increased their position in OPKO Health Inc. [NASDAQ:OPK] by around 29,505,958 shares. Additionally, 112 investors decreased positions by around 23,729,276 shares, while 65 investors held positions by with 142,228,087 shares. The mentioned changes placed institutional holdings at 195,463,321 shares, according to the latest SEC report filing. OPK stock had 36 new institutional investments in for a total of 3,734,253 shares, while 39 institutional investors sold positions of 4,129,410 shares during the same period.